Jyong Biotech (NASDAQ:MENS) Shares Down 2.9% – Should You Sell?

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) fell 2.9% during mid-day trading on Tuesday. The company traded as low as $1.99 and last traded at $2.04. Approximately 22,949 shares were traded during trading, a decline of 49% from the average daily volume of 45,081 shares. The stock had previously closed at $2.10.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, August 19th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Jyong Biotech has an average rating of “Sell”.

Jyong Biotech Stock Down 3.4%

The firm’s 50-day moving average is $2.13 and its 200 day moving average is $2.15.

About Jyong Biotech

Jyong Biotech Limited is a clinical-stage biotechnology company focused on developing and commercializing therapies for prostate diseases. The company’s research centers on botanical and plant-derived drug candidates intended to address conditions including benign prostatic hyperplasia, a noncancerous enlargement of the prostate that can cause urinary symptoms.

Jyong Biotech’s pipeline includes product candidates designed for prostate health and related urological conditions. The company’s development activities have primarily been conducted in China, where it has pursued research, clinical development and regulatory advancement for its candidate therapies.

As a clinical-stage company, Jyong Biotech’s products remain subject to ongoing development and regulatory review, and the timing and outcome of commercialization depend on clinical and regulatory milestones.